Actos and bladder cancer risk

July 2011
Internal Medicine Alert;7/15/2011 Pharmacology Watch, p2
The article reports on the warning issued by the U.S. Food and Drug Administration (FDA) concerning the potential risk of bladder cancer associated with the use of the diabetes drug pioglitazone (Actos).


Related Articles

  • FDA issues pioglitazone warning based on 5-year study results.  // Reactions Weekly;6/25/2011, Issue 1357, p2 

    The article focuses on a study suggesting that the risk of bladder cancer increases with increasing dose and duration of pioglitazone use, which has been released by the U.S. Food and Drug Administration (FDA) as of June 2011.

  • Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting. PICCINNI, CARLO; MOTOLA, DOMENICO; MARCHESINI, GIULIO; POLUZZI, ELISABETTA // Diabetes Care;Jun2011, Vol. 34 Issue 6, p1369 

    OBJECTIVE--To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications. RESEARCH DESIGN AND METHODS--Case/noncase bladder cancer reports associated with antidiabetic drug use were retrieved from the U.S. Food and...

  • Definite signal for bladder cancer associated with pioglitazone.  // Reactions Weekly;5/28/2011, Issue 1353, p4 

    The article reports on the findings of an analysis of data from the U.S. Food and Drug Administration's (FDA) adverse events reporting system (AERS) which confirmed the association between pioglitazone use and bladder cancer. Researchers from the University of Bologna in Italy analyzed 86,987...

  • Actos.  // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10 

    The article reports on the safety review of the diabetic drug, Actos (pioglitazone), conducted by the U.S. Food and Drug Administration (FDA) to determine the association between Actos and the risk of bladder cancer.

  • Concerns about Rezulin grow even stronger. Cerrato, Paul L. // RN;Jul99, Vol. 62 Issue 7, p92 

    Reports on the precautions issued by the United States Food and Drug Administration on the use of antidiabetic agent troglitazone.

  • FDA approved saxagliptin to treat type 2 diabetes.  // Hem/Onc Today;9/10/2009, Vol. 10 Issue 17, p34 

    The article announces that the U.S. Food and Drug Administration (FDA) has approved saxagliptin, an oral hypoglycemic drug, as a treatment for type 2 diabetes.

  • Firms quick to promote alternatives to Rezulin.  // Medical Marketing & Media;May2000, Vol. 35 Issue 5, p18 

    Reports on United States-based pharmaceutical firms' promotion of alternatives to the diabetes drug Rezulin. Warner-Lambert's withdrawal of the drug from the market; Drugs' control of the majority of the market; US Food and Drug Administration's request for the drug's recall.

  • FDA is to assess data linking type 2 diabetes drugs with pancreatitis. Cohen, Deborah // BMJ: British Medical Journal;3/23/2013, Vol. 346 Issue 7900, p2 

    The article mentions the announcement by the US Food and Drug Administration, a consumer protection agency of the US Government, which says that drugs containing glucagon-like peptide-1 (GLP-1) to prevent type 2 diabetes result in causing acute pancreatitis and precancerous pancreatic lesions.

  • FDA Committee Recommends Insulin Therapy.  // BioPharm International;Oct2005, Vol. 18 Issue 10, p14 

    Reports that the U.S. Food and Drug Administration has recommended the use of Exubera, a dry powder to treat adult type 1 and type 2 diabetes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics